bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test Validating ...
SAN ANTONIO--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today ...
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies’ (Nasdaq: BIAF; BIAFW) Vice President of Diagnostics, Jennifer Rebeles, Ph.D., was part of a panel of worldwide experts that published the ...
SAN ANTONIO, Texas--(BUSINESS WIRE)--A new economic study found that adding CyPath® Lung, bioAffinity Technologies’ noninvasive test for detection of early-stage lung cancer, to the standard of care ...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung ...
Study by BAMC’s Michael Morris, M.D., and VA’s Sheila Habib, M.D., evaluated potential economic impact of CyPath® Lung for the early detection of lung cancer “Our study suggests the potential for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results